CardioDiagnostics Acquisition, Valuation, Funding & Investors

CardioDiagnostics was acquired by CardioOne for $567M in April 2025, a 6.9x multiple on $82M of revenue.

CardioDiagnostics acquisition price

$567M

Acquired by CardioOne · Apr 2025

CardioDiagnostics revenue at acquisition

$82M

Last twelve months · Apr 2025

CardioDiagnostics revenue multiple at acquisition

6.9x

EV/Revenue · Apr 2025

Cumulative funding CardioDiagnostics raised

$500K

across 1 funding round

CardioDiagnostics Overview

About CardioDiagnostics

CardioDiagnostics is a U.S.-headquartered medtech company with global R&D centers developing wireless cardiac monitoring devices. Its proprietary technologies enable continuous patient tracking while maintaining daily activities, supplying physicians with diagnostic data for arrhythmia and heart failure management.


Founded

2010

HQ

United StatesWilmington, DE

Status

Acquired

Customer focus

B2B

Revenue model

Product sales

Revenue

$82M (Apr 2025)

Valuation

$567M (acquired Apr 2025)

CardioDiagnostics Acquisition

CardioDiagnostics was acquired by CardioOne for $567M on 24 April 2025.

The acquisition price implies a 6.9x revenue multiple on $82M of revenue.

Before the acquisition CardioDiagnostics had raised $500K across 1 funding round.

CardioOne, a national growth and operational partner for independent cardiology practices backed by WindRose Health Investors since March 2024, completed the acquisition of CardioDiagnostics on April 24, 2025. CardioDiagnostics specializes in advanced cardiac monitoring solutions, including electrocardiogram (ECG) technology, remote patient monitoring (RPM), cloud-based analytics, and diagnostics that provide healthcare providers with real-time insights for early detection and improved cardiovascular patient outcomes. The deal, advised by Alantra on the sell-side, integrates CardioDiagnostics' capabilities into CardioOne's comprehensive practice management platform to create a leading virtual care solution combining care management, remote monitoring, and operational support for cardiologists. Strategic rationale centers on enhancing CardioOne's end-to-end technology offerings to help independent practices thrive amid value-based care shifts, with CardioDiagnostics founder Ziad Sankari motivated by personal loss to his father from a heart condition and a vision to transform cardiology. CardioOne co-founder and CEO Jasen Gundersen emphasized shared values in advancing patient care and practice growth. No financial terms were disclosed, but existing CardioDiagnostics customers face no service disruptions and gain expanded capabilities through continued investment. The transaction positions the combined entity to drive innovation in cardiac care, optimizing practice management in a competitive landscape where cardiology platforms consolidate to embed RPM and analytics, as evidenced by CardioOne's prior funding for technology expansion.

CardioDiagnostics acquisition details
AcquirerDateTypePriceEV/Revenue
  • CardioOne
24 Apr 2025Strategic M&A$567M6.9x

CardioDiagnostics Funding History

CardioDiagnostics has raised a total of $500K across 1 funding round.

CardioDiagnostics funding rounds

CardioDiagnostics funding rounds
DateStageInvestorsRaised
Nov 2015SeedBeryTech Fund$500K

Who has invested in CardioDiagnostics?

1 investor has backed CardioDiagnostics across its funding rounds, including BeryTech Fund.


CardioDiagnostics Investors

Investors in CardioDiagnostics by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 1 CardioDiagnostics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

CardioDiagnostics Competitors

CardioDiagnostics competitors include listed companies like TaiDoc Technology, Delcath Systems and Sunmax Biotechnology, and private ones like Petmate, DNAnexus and Galvanize Therapeutics.

Public and private companies comparable to CardioDiagnostics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
TaiDoc TechnologyTaiwanTaiwanPublicly listed$132M$58M$431M-
PetmateUnited StatesSan Francisco, CAPrivate--$420M-
Delcath SystemsUnited StatesUnited StatesPublicly listed$85M$939K$564M4.7x
DNAnexusUnited StatesSan Francisco, CAPrivate--$600M-
Galvanize TherapeuticsUnited StatesSan Francisco, CAPrivate--$650M-
Sunmax BiotechnologyTaiwanTaiwanPublicly listed$64M$35M$670M-

CardioDiagnostics Public Comps

CardioDiagnostics is no longer listed, but its public comps include OrthoPediatrics, Delcath Systems, Ocumension, BrainsWay, Curiox Biosystems, SD Biosensor, Cerus, Veradigm, Nanosonics and Oculis Holding.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
OrthoPediatrics$236M($12M)2.6x2.4x(51.6x)28.2x
Delcath Systems$85M$939K5.5x4.7x501.0x28.4x
Ocumension$120M($3M)4.1x-(178.3x)-
BrainsWay$52M$7M9.3x7.6x71.7x41.7x
Curiox Biosystems$4M($17M)156.6x-(33.9x)-
SD Biosensor$517M($509M)0.8x-(0.8x)-
Cerus$206M($5M)2.7x2.2x(112.8x)42.1x
Veradigm$588M$54M0.9x0.9x9.8x6.8x

This data is available for Pro users. Sign up to see all CardioDiagnostics competitors and their valuation data.

Start Free Trial

Common questions about CardioDiagnostics

When was CardioDiagnostics founded?CardioDiagnostics was founded in 2010.
Where is CardioDiagnostics headquartered?CardioDiagnostics is headquartered in Wilmington, DE, United States.
Is CardioDiagnostics publicly listed?No, CardioDiagnostics was acquired by CardioOne in April 2025.
Who acquired CardioDiagnostics?CardioDiagnostics was acquired by CardioOne in April 2025.
How much was CardioDiagnostics acquired for?CardioDiagnostics was acquired for $567M in April 2025, a 6.9x revenue multiple.
How much funding has CardioDiagnostics raised?CardioDiagnostics has raised $500K across 1 funding round.
What was CardioDiagnostics' last funding round?CardioDiagnostics' last funding round was a $500K seed round in November 2015.
Who are CardioDiagnostics' investors?CardioDiagnostics' investors include BeryTech Fund.
Which companies are comparable to CardioDiagnostics?Companies comparable to CardioDiagnostics include TaiDoc Technology, Petmate, Delcath Systems, DNAnexus, Galvanize Therapeutics and Sunmax Biotechnology.

See companies similar to CardioDiagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial